|
| 38031764 | B-cell acute lymphoblastic leukemia and juvenile xanthogranuloma in a patient with <i>ETV6</i> thrombocytopenia and leukemia predisposition syndrome: novel clinical presentation and perspective. | Haematologica | 2024 |
| 38031764 | B-cell acute lymphoblastic leukemia and juvenile xanthogranuloma in a patient with <i>ETV6</i> thrombocytopenia and leukemia predisposition syndrome: novel clinical presentation and perspective. | Haematologica | 2024 |
| 37890130 | Future of Treatment of Adolescents and Young Adults With ALL: A Vision for Collaboration and Equity. | J Clin Oncol | 2024 |
| 37890117 | Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. | J Clin Oncol | 2024 |
| 38062123 | Development of osteonecrosis and improved survival in B-ALL: results of Children's Oncology Group Trial AALL0232. | Leukemia | 2024 |
| 38062123 | Development of osteonecrosis and improved survival in B-ALL: results of Children's Oncology Group Trial AALL0232. | Leukemia | 2024 |
| 37890130 | Future of Treatment of Adolescents and Young Adults With ALL: A Vision for Collaboration and Equity. | J Clin Oncol | 2024 |
| 37890117 | Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. | J Clin Oncol | 2024 |
| 36256911 | Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study. | J Clin Oncol | 2023 |
| 35484682 | Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement. | Haematologica | 2023 |
| 36256911 | Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study. | J Clin Oncol | 2023 |
| 37592363 | Assessment of proxy-reported responses as predictors of motor and sensory peripheral neuropathy in children with B-lymphoblastic leukemia. | Pediatr Blood Cancer | 2023 |
| 37820294 | Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL. | J Clin Oncol | 2023 |
| 37584517 | Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors. | Cancer Res | 2023 |
| 37556734 | Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. | Blood | 2023 |
| 37961674 | Identification and targeting of treatment resistant progenitor populations in T-cell Acute Lymphoblastic Leukemia. | Res Sq | 2023 |
| 37157018 | Correction: Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932. | Leukemia | 2023 |
| 37407142 | Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. | Lancet Haematol | 2023 |
| 36966262 | Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932. | Leukemia | 2023 |
| 36576946 | Identification of TCF3 germline variants in pediatric B-cell acute lymphoblastic leukemia. | Blood Adv | 2023 |
| 37259259 | Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631. | Pediatr Blood Cancer | 2023 |
| 37257143 | Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse. | J Clin Oncol | 2023 |
| 37001051 | Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. | Blood | 2023 |
| 36861410 | <i>KMT2A</i> partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children's Oncology Group P9407 trial study. | Haematologica | 2023 |
| 36603187 | Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report. | Blood | 2023 |
| 36725118 | Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. | Lancet Haematol | 2023 |
| 37503171 | Germline Genetic <i>NBN</i> Variation and Predisposition to B-cell Acute Lymphoblastic Leukemia in Children. | Res Sq | 2023 |
| 37961674 | Identification and targeting of treatment resistant progenitor populations in T-cell Acute Lymphoblastic Leukemia. | Res Sq | 2023 |
| 37592363 | Assessment of proxy-reported responses as predictors of motor and sensory peripheral neuropathy in children with B-lymphoblastic leukemia. | Pediatr Blood Cancer | 2023 |
| 37556734 | Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. | Blood | 2023 |
| 37584517 | Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors. | Cancer Res | 2023 |
| 37503171 | Germline Genetic <i>NBN</i> Variation and Predisposition to B-cell Acute Lymphoblastic Leukemia in Children. | Res Sq | 2023 |
| 37820294 | Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL. | J Clin Oncol | 2023 |
| 35484682 | Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement. | Haematologica | 2023 |
| 37259259 | Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631. | Pediatr Blood Cancer | 2023 |
| 37257143 | Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse. | J Clin Oncol | 2023 |
| 37157018 | Correction: Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932. | Leukemia | 2023 |
| 37407142 | Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. | Lancet Haematol | 2023 |
| 37001051 | Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. | Blood | 2023 |
| 36966262 | Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932. | Leukemia | 2023 |
| 36725118 | Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. | Lancet Haematol | 2023 |
| 36576946 | Identification of TCF3 germline variants in pediatric B-cell acute lymphoblastic leukemia. | Blood Adv | 2023 |
| 36603187 | Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report. | Blood | 2023 |
| 36861410 | <i>KMT2A</i> partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children's Oncology Group P9407 trial study. | Haematologica | 2023 |
| 33197607 | The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities. | Semin Cancer Biol | 2022 |
| 35575404 | Molecular Mechanisms of ARID5B-Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia. | J Natl Cancer Inst | 2022 |
| 35552709 | Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. | J Natl Cancer Inst | 2022 |
| 35411095 | JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. | Leukemia | 2022 |
| 36050548 | The genomic landscape of pediatric acute lymphoblastic leukemia. | Nat Genet | 2022 |
| 36518527 | A convergent malignant phenotype in B-cell acute lymphoblastic leukemia involving the splicing factor SRRM1. | NAR Cancer | 2022 |